Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3Phase NA 1Phase 1/2 1

Status

Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 41Lymphoid 10Gastrointestinal 8Other hematologic neoplasm 6Thoracic 5Gynecologic 5Tumor-Agnostic 3Sarcoma 3Other solid neoplasm 3Head & Neck 3Genitourinary 3Plasma cell 2Dermatologic 2CNS 2Other neoplasm 1Myeloid 1Classical hematology 1

Conditions

Neoplasms 2Neoplasm Metastasis 1

Interventions

pembrolizumab 46Paclitaxel 46Gemcitabine 41Carboplatin 37Docetaxel 35Bevacizumab 27Cisplatin 25Irinotecan 22Nivolumab 20Fluorouracil 20Erlotinib Hydrochloride 18Pemetrexed 17Capecitabine 17Sorafenib 16Magnetic Resonance Spectroscopy 16Cetuximab 16Afatinib 16Leucovorin 15regorafenib 14olaparib 13Specimen Handling 13Oxaliplatin 13trametinib 12Biopsy 12130-nm albumin-bound paclitaxel 11eribulin 10atezolizumab 10epothilone B 9Radiotherapy 9Midazolam 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × palbociclib × Tumor-Agnostic × Clear all
NCT06997029 2026-04-21

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

Bristol-Myers Squibb

Phase 1 Recruiting
234 enrolled
Tumor-Agnostic

Neoplasms

NCT03065387 2026-01-12

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
93 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT01522989 2020-03-04

PD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor Malignancies

Georgetown University

Phase 1 Unknown
37 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡